X
xCures
AI-powered platform providing real-time healthcare data for treatment decision support and actionable insights
About xCures
xCures, founded in 2018, operates in the healthcare sector, focusing on leveraging artificial intelligence (AI) to improve patient outcomes. The company provides a platform that extracts, normalizes, and structures real-time healthcare data to support treatment decisions. This platform is particularly beneficial for oncologists and cancer patients, offering rapid and comprehensive access to critical data and actionable insights. xCures primarily serves healthcare providers, researchers, and pharmaceutical companies. The business model revolves around licensing its AI-powered platform to these clients, generating revenue through subscription fees and data analytics services. By addressing the complexities of large-scale cancer patient data and fragmented medical records, xCures aims to transform healthcare data into clinically actionable insights. The company also collaborates with other entities to enhance precision medicine guidelines and support investigational cancer treatments. Keywords: AI, healthcare, oncology, data analytics, real-time data, treatment support, precision medicine, cancer research, clinical insights, subscription model.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Oakland, United States
- Employees
- 58
- Open positions
- 2
- Dealroom signal
- 88.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Core AI, Precision Medicine, Biotech and Pharma, AI Drug Discovery, Techbio, Hard Tech, AI Applications, DT and LS
- Technology
- Artificial Intelligence
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jun 2026 | $46M | $127M | Spring Mountain Capital · Innovius Capital | ↗ |
| CONVERTIBLEOther financing | Dec 2023 | $0 | — | HealthTech Capital | ↗ |
Growth signals
Latest recorded traffic for xCures is 50K monthly website visits, up 117.4% over the last three months. xCures's team grew 31.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
HealthTech Capital
Innovius Capital
Spring Mountain Capital
Other known investors2 additional known investors
Lauder Partners
Vanedge Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about xCures on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See xCures’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.